Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: A randomized controlled trial

Journal of Clinical Gastroenterology

Volumn 43, Issue 2, 2009, Pages 140-146

  De Leest, Helena T J I ^a   Steen, Kirsti S ^a   Bloemena, Elisabeth ^a   Lems, Willem F ^a   Kuipers, Ernst J ^f   Van De Laar, Mart A F J ^b   Bijlsma, J W J ^c   Janssen, Matthijs ^d   Houben, Harry H M L ^e   Kostense, Piet J ^a   Boers, Maarten ^a   Dijkmans, Ben A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

^e Sittard Geleen Heerlen   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Gastritis histology; Helicobacter pylori; Nonsteroidal anti inflammatory drugs; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; ANTIINFECTIVE AGENT; ANTIULCER AGENT;

ARTICLE; ATROPHY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ERADICATION THERAPY; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ANTRUM; STOMACH DISEASE; STOMACH MUCOSA; AGED; DRUG COMBINATION; DRUG EFFECT; HOSPITALIZATION; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

AGED; AMOXICILLIN; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 64749115623     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181595b40     Document Type: Article

References (34)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899. (Pubitemid 29272670)
2. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
3. Rostom A, Dube C, Wells G, et al. Prevention of NSAIDinduced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;CD002296.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528. (Pubitemid 30844348)
5. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359:9-13.
6. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998; 352:1016-1021.
7. Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut. 2002;51:329-335. (Pubitemid 34907698)
8. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311-1315.
9. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-789. (Pubitemid 34940841)
10. Ekstrom AM, Held M, Hansson LE, et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology. 2001;121:784-791. (Pubitemid 32959388)
11. Laine L. Review article: the effect of Helicobacter pylori infection on nonsteroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Aliment Pharmacol Ther. 2002;16(suppl 1):34-39. (Pubitemid 41759565)
12. Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med. 2001;134: 380-386. (Pubitemid 32179477)
13. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119: 7-14.
14. van der Hulst RW, van der EA, Dekker FW, et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology. 1997;113:25-30. (Pubitemid 27281754)
15. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut. 2000;46:615-621. (Pubitemid 30305777)
16. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut. 2004;53:12-20.
17. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic GERD Study Group. Gastroenterology. 1999;117:319-326.
18. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection- The Maastricht III Consensus Report. Gut. 2007;6:772-781. (Pubitemid 46854190)
19. Lerang F, Moum B, Mowinckel P, et al. Accuracy of seven different tests for the diagnosis of Helicobacter pylori infection and the impact of H2-receptor antagonists on test results. Scand J Gastroenterol. 1998;33:364-369. (Pubitemid 28212548)
20. Meijer BC, Thijs JC, Kleibeuker JH, et al. Evaluation of eight enzyme immunoassays for detection of immunoglobulin G against Helicobacter pylori. J Clin Microbiol. 1997;35: 292-294. (Pubitemid 26422677)
21. van de Wouw BA, de Boer WA, Jansz AR, et al. Comparison of three commercially available enzyme-linked immunosorbent assays and biopsy-dependent diagnosis for detecting Helicobacter pylori infection. J Clin Microbiol. 1996;34: 94-97.
22. de Leest HTJI, Steen KSS, Lems WF, et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID-treatment: double-blind, randomized, placebo-controlled trial. Helicobacter. 2007;5:477-485.
23. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-1181.
24. Shiotani A, Yamaoka Y, El Zimaity HM, et al. NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite. Dig Dis Sci. 2002;47:38-43. (Pubitemid 34075014)
25. Goggin PM, Collins DA, Jazrawi RP, et al. Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis. Gut. 1993;34: 1677-1680.
26. Frezza M, Gorji N, Melato M. The histopathology of nonsteroidal anti-inflammatory drug induced gastroduodenal damage: correlation with Helicobacter pylori, ulcers, and haemorrhagic events. J Clin Pathol. 2001;54:521-525. (Pubitemid 32642940)
27. Taha AS, Dahill S, Morran C, et al. Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers. Gastroenterology. 1999;116:254-258.
28. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345: 1525-1528.
29. Logan RP, Walker MM, Misiewicz JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut. 1995;36:12-16.
30. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018-1022. (Pubitemid 26123777)
31. van Grieken NC, Meijer GA, Weiss MM, et al. Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study. Am J Gastroenterol. 2001;96:2882-2886.
32. van Grieken NC, Meijer GA, Kale I, et al. Quantitative assessment of gastric antrum atrophy shows restitution to normal histology after Helicobacter pylori eradication. Digestion. 2004;69:27-33. (Pubitemid 38332922)
33. Dixon MF, O'Connor HJ, Axon AT, et al. Reflux gastritis: distinct histopathological entity? J Clin Pathol. 1986;39: 524-530.
34. El Zimaity HM, Genta RM, Graham DY. Histological features do not define NSAID-induced gastritis. Hum Pathol. 1996;27:1348-1354.